Hola,
Are you new here?

IMPORTANT

financed

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in...

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical benefit from the addition of CDK 4/6-inhibitors to endocrine therapy but with higher risk for... see more

30/04/2028

Region Örebro Coun...

5M€

Project Budget: 5M€

Project leader

OREBRO LANS LANDSTING No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 20 Participantes

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2023-04-24

HORIZON-MISS-2022-CANCER-01-03: Pragmatic clinical trials to optimi... Expected Outcome:While cancer research and innovation have generated novel treatment options, cancer...

I+D

Cerrada

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

20 Participantes

Region Örebro County

696.25K€ | Leader

UNED

195.00K€ | participant

HUS

329.25K€ | participant

PHAZE CLINICAL RESEARCH & PH...

487.50K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 60 months Date Start: 2023-04-24
End date: 2028-04-30

Project leader

OREBRO LANS LANDSTING No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 5M€

participation deadline Sin fecha límite de participación.

Project description Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical benefit from the addition of CDK 4/6-inhibitors to endocrine therapy but with higher risk for adverse events and treatment discontinuation compared to younger patients. The IMPORTANT project will design and conduct a pragmatic clinical study with a decentralised approach for older patients with advanced breast cancer aiming at high level of evidence (level I) with multi-layer results that can enable changes in current clinical practice. This study will be conducted across 6 (six) EU countries, and will include more than 500 female and male patients. The project will also perform a series of analyses over a) a wide range of clinical-relevant primary and secondary endpoints targeting to contribute to current clinical practice and b) the implementation of specific strategies aiming at more individualized treatment and follow-up approaches to a clinical trial setting that highly resembles real-world setting due to the trial's pragmatic design. The project will be developed in 60 months by a competitive consortium of 19 partners from 11 countries, which corresponds to a well-balanced structure, involving clinical sites, SMEs, universities and patient advocacy organizations. Despite the great diversity of entities within the proposal, IMPORTANT partners bring state-of-the-art complementary skills ensuring the ability of the consortium to successfully complete the proposed work.This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers